ELTX (Elicio Therapeutics) ROC (Joel Greenblatt) %: -925.78% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELTX Elicio Therapeutics Inc ELTX
32 GF Score
Price $2.99
! 1 Warning Sign
View Full Analysis

What is Elicio Therapeutics ROC (Joel Greenblatt) %?

Elicio Therapeutics ELTX -3.86% 32 ROC (Joel Greenblatt) % is -925.78% as of Mar. 2026. GuruFocus rates ELTX with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,323 Biotechnology companies, Elicio Therapeutics ranks worse than 63.19% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Elicio Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -925.78%.

The historical rank and industry rank for Elicio Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

ELTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2667.08   Med: -763.87   Max: -432.73
Current: -725.54

During the past 7 years, Elicio Therapeutics's highest ROC (Joel Greenblatt) % was -432.73%. The lowest was -2667.08%. And the median was -763.87%.

ELTX's ROC (Joel Greenblatt) % is ranked worse than
63.19% of 1323 companies
in the Biotechnology industry
Industry Median: -296.6 vs ELTX: -725.54

Elicio Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 18.40% per year.


Elicio Therapeutics  (NAS:ELTX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Elicio Therapeutics ROC (Joel Greenblatt) % Related Terms


Elicio Therapeutics ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Elicio Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicio Therapeutics ROC (Joel Greenblatt) % Chart

Elicio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -2,667.08 -524.36 -432.73 -763.87 -682.37

Elicio Therapeutics Quarterly Data
Mar20 Dec20 Mar21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -729.45 -718.62 -703.80 -566.46 -925.78

ELTX vs GOSS, GANX, ACET: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Elicio Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elicio Therapeutics ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Elicio Therapeutics's ROC (Joel Greenblatt) % falls into.


ELTX
32GF Score
Elicio Therapeutics Inc ELTX
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicio Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.748) - (4.571 + 0 + 2.528)
=-6.351

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.252) - (5.354 + 0 + 0.833)
=-4.935

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Elicio Therapeutics for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-45.664/( ( (5.077 + max(-6.351, 0)) + (4.788 + max(-4.935, 0)) )/ 2 )
=-45.664/( ( 5.077 + 4.788 )/ 2 )
=-45.664/4.9325
=-925.78 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -925.78% mean?
Elicio Therapeutics (ELTX) has a ROC (Joel Greenblatt) % of -925.78% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Elicio Therapeutics and its competitors. According to the industry distribution chart, Elicio Therapeutics ranks #836 out of 1323 companies in the Biotechnology industry, placing it in the top 63.2%.
Is Elicio Therapeutics' ROC (Joel Greenblatt) % too high?
Elicio Therapeutics' current ROC (Joel Greenblatt) % is -925.78%. Based on the distribution chart, Elicio Therapeutics ranks #836 out of 1323 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Elicio Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' ROC (Joel Greenblatt) % compare to GOSS and GANX?
According to the Biotechnology industry distribution chart, Elicio Therapeutics ranks #836 out of 1323 companies for ROC (Joel Greenblatt) %. This places Elicio Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Elicio Therapeutics and its competitors. Elicio Therapeutics's current ROC (Joel Greenblatt) % is -925.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (ELTX) has a current ROC (Joel Greenblatt) % of -925.78%. The current ROC (Joel Greenblatt) % is -925.78%. Elicio Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Elicio Therapeutics (ELTX), the current ROC (Joel Greenblatt) % is -925.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicio Therapeutics Business Description

Other Exchanges 9HA:Germany
Address 451 D Street, Suite 501, 5th Floor, Boston, MA, USA, 02210
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
32GF Score

Get the complete analysis for ELTX

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.99
Price